Extra pembrolizumab after surgery for early-stage triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests if giving more of the immunotherapy drug pembrolizumab (Keytruda) after surgery helps people with early-stage triple-negative breast cancer that did not completely disappear with the initial chemotherapy plus immunotherapy. This is for patients who still have some cancer left after surgery, to reduce the chance of it coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Before starting chemotherapy, your breast cancer was stage II or III and triple-negative (that means hormone receptors and HER2-negative).
- You had chemotherapy plus the immunotherapy drug pembrolizumab (Keytruda) before surgery, for at least 8–12 weeks.
- After surgery, some cancer remained (residual disease) and you are planning to take capecitabine or olaparib as standard follow-up.
- You had surgery within the last 12 weeks.
- You are generally healthy enough to participate (WHO performance status 0-2) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different sequences of chemotherapy combined with pembrolizumab (an immunotherapy drug) given before surgery for high-risk triple-negative breast cancer. The goal is to see which sequence works better at shrinking or eliminating the tumor.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy before surgery improves immune and clinical responses in people with early-stage triple-negative breast cancer. You may benefit by getting a potentially more effective treatment plan, while the study team closely monitors your response.
Hear when a new Triple Negative Breast Cancer (TNBC), Early Setting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.